Uppsala University Hospital chooses AI-based Qlucore Insights to develop precision diagnostics
Qlucore, a driving force in software development for precision diagnostics of cancer, has signed an agreement with Uppsala University Hospital. The hospital will use the Qlucore Insights software to improve the analysis of acute lymphoblastic leukemia (ALL) in children. ALL is the most common form of childhood leukemia - 90% of children who get leukemia are affected by ALL.
Qlucore already has customers in Denmark, Sweden, and Italy who use the software. The agreement for precision diagnostics will be the second signed in Sweden in a short time. The goal is to help customers develop analyses that contribute to a more accurate diagnosis and thus a better choice of treatment.
"Our solutions use AI-based machine learning and will facilitate and enable improved analysis of cancer, in this case acute lymphoblastic leukemia (ALL). The goal is to make it easier for doctors to make a diagnosis and decide how to treat the disease”, says Carl-Johan Ivarsson, CEO of Qlucore.
Cancer diagnostics are changing rapidly and Qlucore is at the forefront of this development. The unique software combines advanced visualization, mathematics, and biology. The company's advanced software creates the conditions for more precise cancer diagnostics where AI-based machine learning makes it possible to place a sample in the right subgroup.
Qlucore Insights is available for research and work to achieve CE marking is ongoing. The CE-marked product will be called Qlucore Diagnostics.
